Incretin therapy for obesity: reality and prospects
Clinical review for general practice · 19.06.2026 · 7 (4) · 70-72
DOI: 10.47407/kr2026.7.4.00824 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 19.06.2026. Verfasst von Merdzhen M Orazova und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Obesity represents a global non-infectious pandemic of the 21st century. More than 2 billion people all over the world suffer from obesity and, according to forecasts, the number of such people will increase to almost two thirds of the Earth’s population by the year 2050. In recent years, obesity treatment methods changed dramatically from previous decades. The emergence of incretin-based drugs increased the potential for medical control of body weight and metabolic health in obesity in order to prevent cardiometabolic, carcinogenic, and other complications in the long term. The review considers physiological and pharmacological aspects of incretin therapy for obesity, accessibility and prospects of novel therapeutic combinations, such as dual and triple glucagon-like peptide-1 receptor agonists, with the aim of treatment strategy personalization and individualization. Keywords: obesity, incretins, weight-loss pharmacotherapy, glucagon-like peptide-1 receptor agonists.
Zitieren
APA
Orazova, M. M., & Radzinsky, V. E. (2026). Incretin therapy for obesity: reality and prospects. Clinical review for general practice, 7(4), 70-72. https://doi.org/10.47407/kr2026.7.4.00824
Vancouver
Orazova MM, Radzinsky VE. Incretin therapy for obesity: reality and prospects. Clinical review for general practice. 2026;7(4):70-72. doi:10.47407/kr2026.7.4.00824
BibTeX
@article{Orazova2026,
author = {Orazova, Merdzhen M and Radzinsky, Viktor E},
title = {Incretin therapy for obesity: reality and prospects},
journal = {Clinical review for general practice},
year = {2026},
volume = {7},
number = {4},
pages = {70--72},
doi = {10.47407/kr2026.7.4.00824}
}
EUVIMED